

28<sup>th</sup> September, 2015

BSE Limited  
P.J. Towers, Dalal Street,  
Mumbai – 400 001

Dear Madam,

**Kind Attn.: Ms. Usha Sharma/ Ms. Tina Jain**

**Sub: Clarification on news item appeared in “The Economic Times”**

This refers to your letter dated 28<sup>th</sup> September, 2015 regarding the news item appeared in “The Economic Times” on 26<sup>th</sup> & 28<sup>th</sup> September, 2015.

In this regard, we have to inform you that the Company has not received any such communication as mentioned in the said news item from US FDA.

Please note that earlier on 27<sup>th</sup> May, 2015, the Company has informed Exchanges about completion of inspection at our manufacturing unit at Waluz, Aurangabad by US FDA (copy enclosed).

As a standard protocol, the Company keep the Stock Exchanges informed about any price sensitive information under Clause 36 of the Listing Agreement or other relevant applicable laws.

Kindly take the same on your records and acknowledge.

For **Wockhardt Limited**



**Narendra Singh**  
Company Secretary

Encl: As Above



May 27, 2015

**BSE Limited**  
Corporate Relations Department  
P J Towers  
Dalal Street  
Mumbai 400 001

Dear Sir / Madam,

Scrip Code : 532300

This is to inform you the exchange that inspection of our manufacturing unit at H14/2 Waluj, Aurangabad, Maharashtra by US FDA has since been completed.

As a standard protocol of the Organization we keep the Stock Exchange informed about any price sensitive information under clause 36 of the Listing Agreement or other relevant applicable laws

This is for your information and records.

Thanking you,

Yours cordially,

For **WOCKHARDT LIMITED**



**AMRUTA AVASARE**  
**ASSISTANT COMPANY SECRETARY**